Trial Profile
A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Chronic Kidney Disease and Hyperkalemia (EMERALD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- Acronyms EMERALD
- Sponsors CSL Vifor; Relypsa; Vifor
- 28 Nov 2022 This trial has been completed in Germany(Global end date 13 May 2022), according to European Clinical Trials Database record.
- 10 Jun 2022 Status changed from suspended to discontinued.
- 02 Jun 2022 This trial has been discontinued in (End Date: 13 May 2022), according to European Clinical Trials Database record.